Adult volunteers who have no problems with motor and metabolic functions.
Conditions
Interventions
None listed
Sponsors
Maruzen Pharmaceuticals Co., LTD.
Professor Hiroharu Kamioka, Graduate School of Tokyo University of Agriculture The lead principal investigator is enrolled in the doctoral program at the Graduate School of Tokyo University of Agriculture.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants: Adult volunteers who have no problems with motor and metabolic functions. *1 Intervention: One-time or continuous intake of food containing Panax genus plants, or their extract (more than 100mg/day), or ginsenosides (more than 4mg/day) *2 Comparison: Intake of placebo food. Outcome: Primary outcome: exercise endurance. Study design: randomized, double-blind, placebo-controlled parallel group trial / randomized, double-blinded, placebo-controlled cross-over trial/ quasi-randomized, double-blind, placebo-controlled controlled trial. The literature to be included will be made up of original papers, information on clinical trial registered databases, abstracts, and grey literature. The keywords used in the literature search will be in English or Japanese only. Hand-search will also be conducted on some scientific journals. *1: Studies with participants who have characteristic exercise ability like athletes, belong sports teams or military will be included but will be subgroup analysis. Studies with participants who have disease or illness will be included, except those affected by disease impacting their physical exercise ability. Participants with diseases related to motor function of the limbs judged to have physical exercise ability will be included. *2: According to previous study, single intake and continuous intake up to 12 weeks was included.
Exclusion criteria
Exclusion criteria: Literature which does not meet key inclusion criteria will be excluded. Participants who are planning or currently pregnant or breastfeeding, and children (persons under 18 years), will be excluded from this study. If participants have conditions such as any acute or chronic diseases: cardiovascular, pulmonary, endocrine system, gastrointestinal system, and other organ dysfunction, or cancer, they will be excluded. The studies will be excluded from using special dosage form food like foods to avoid digestion or absorption by the gastrointestinal system as intervention foods. For the control group, no intervention is excluded. Literature not written in English or Japanese will be excluded due to inability to verify and perform data extraction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Exercise endurance. | — |
Countries
Japan
Contacts
Public ContactShingo Ikeuchi
Maruzen Pharmaceuticals Co.,Ltd. Research & Development div.
Outcome results
None listed